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peak & trough cones, and AVC were examined to determine if they shifted
the hazard function for TVC in a Cox model.Results: Viral titers were
measurable in 70 subjects. TVC for 50% of the population was 85.5,78.5,
70.0,64.5 and 63.0 hn for the placebo, 100 mg QD, 200 mg QD, 400 mg QD
and 200 mg Q12 h regimens, respectively. Baseline viral titer, R WJ-270201
peak cone, trough cone, and AUC significantly affected TVC, whereas
schedule of R WJ-270201 administration did not. Only baseline viral titer
and AUC of R WJ-270201 were included in the final model.Conclusions:
R WJ-270201 and baseline viral titer significantly altered the TVC. The
schedule of administration did not affect TVC, indicating that once daily
administration ofRWJ-270201 is appropriate. This was validated by AUC
ofRWJ-270201 being chosen as the dynamically linked variable.
non-linear pharmacokinetics. There was notable inter-subject variability in
Cmax and AUCT and a low intra-subject variability. Voriconazole was well
tolerated. The most frequent treatment-related adverse events were abnor-
mal vision, headache and dizziness. Adverse events were mild and resolved
without intervention.
Conclusions: Voriconazole appeared to be well tolerated in this study. The
dosing regimens studied yielded plasma levels above in vitro MICs for
Aspergillus spp. and most emerging fungal pathogens. Further studies are
warranted to investigate the efficacy ofvoriconazole in treatment ofsystemic
fungal infections.
Table 1. Mean parameters in plasma at different doses
Table 1. Geometric means for pharmacokinetic parameters in plasma
IMo0261 Two single-blinded. p1acebo-controlled studies on
the pharmacokinetics of intravenous voriconazole - a novel
broad-spectrum antifungal agent
P. Ghahramani, L. Purkins, D. J. Nichols
jJ{izer Central ResearchUnited Kingdom
Objectives: To investigate the pharmacokinetics of voriconazole after
multiple intravenous dosing. Also, to invcstigate the effect of loading
doses of voriconazole on time to achieve steady-state concentrations.
Methods: Two single-blinded studies were performed. Study A (n = 12):
subjects received intravenous voriconazole (3 mg/kg, n = 9) or placebo (n
= 3), administered once daily on days 1 and 12, and bid on days 3 to 11.
Study B (n = 18): subjects were randomized to intravenous voriconazole (n
= 9) or placebo (n = 9), with voriconazole being administered 6 mg/kg bid
on day 1, followed by 3 mg/kg bid from day 2 to the morning of day 10.
Blood samples were collected pre-dose and up to 48 h post-dose on day 1 and
on the last day of dosing.
Results: Maximum plasma concentration (Cmax) and area under the
plasma concentration-time curve data within a dosing interval (AUCr )
are shown in Table 1. Trough concentrations ofvoriconazole at steady-state
were > 800 ng/ml which is above the in vitro MICs for most fungal
pathogens. Steady-state in study A was reached by about day 6 however in
study B it was reached within 48 h of initial dosing. In Study A, Cnux and
AUCr after multiple dosing were 3.2- and 1.7-fold higherthan that ofsingle
dose, respectively. These data are consistent with dose dependent pharma-
cokinetics.
Conclusions: The dosing regimens studied produce plasma voriconazole
concentrations above MIC90s for most fungal pathogens in vitro. Use of










Day 1 Day 10
4675 ~
13217 13245
Parameter Day Dose (mgflcg)
2 hid 40d 1.5 tid 2 tid 3 bid
Cm•• (ng/mI)· 1 485 1570 364 646 1194
12 1007 2066 1106 2184 2356
AVCr (ng h/ml). 1 1179 5896 882 1435 3145
12 4296 13185 3789 9044 11170
llf2 (h) 1 4.7 6.0 3.3 5.3 5.5
12 6.5 6.6 6.4 7.3 6.4
• Geometric mean
P:13/1 - Pharmacoanalytics and pharmacokinetics
IMoP239I A simple. High Performance liquid
Chromatography (HPLC) assay for the oxazolidinone linezolid
(LZD) in human serum
C. Tobin,J. Sunderland, L. White, A. MacGowan
BCARE, Southmead Hospital, Bristol, United Kingdom
Objectives: To develop an HPLC assay for monitoring LZD in human
serum.
Method: Stationary phase - Hypersil SODS II (10 cm x 4.6 mm); mobile
phase - 1% phosphoric acid, 30% methanol, 2 gfL heptane sulphonic acid,
adjusted to pH 5; solvent flow rate 1.0 mL/min; detection by uv absorbance
(254 nm). Sample preparation - specimen mixed 1:1 with acetonitrile and
centrifuged. Injection volume 20 1£1.
Results: The retention time of LZD was 6 min. The reproducibility was
< 6% coefficient ofvariation for a serum sample containing 2.2 mgfL LZD.
The delection limit was 0.05 mg/L. Linearity for 0, 0.1, 0.4, 0.8, 2.0 & 5.0
mg/L LZD was good for both aqueous and serum samples (r = 0.9996 and
0.9993, respectively); serum recovery approached 100% at all these con-
centrations. There was no interference from 23 commonly used antibiotics
or from 12 samples of sera from patients receiving antibiotics other than
LZD. Only benzylpenicillin resulted in low level interference (20 mg/L
equivalent to 0.35 mg/L LZD) but was easily removed by ,B-Iactamase.
ConclusIon: This rapid assay is ideally suited to the busy clinical laboratory.
IMo027! The pharmacokinetics and safety of oral
voriconazole: A novel broad-spectrum antifungal agent
P. Ghahramani, L. Purkins, M.J. Allen
Pfizer Central Research , United Kingdom
Objectives: To investigate the pharmacokinetics, safety and toleration of
voriconazole after a range of single and multiple oral doses.
Methods: This was a single-blinded, parallel group study. 64 healthy males
were randomized to voriconazole doses (mg/kg) of: 2 bid (n = 8),4 od (n =
8), 1.5 tid (n = 11), 2 tid (n = 8), 3 bid (n = 8) and placebo (n = 21).
Voriconazole was administered as single dose on days 1 and 12, and multiple
dose on days 3-11. Blood samples were collected pre-dose and up to 48 h
post-dose on days 1 and 12. Physical examination, ECG and routine clinical
laboratory tests were performed at screening, during the study and at follow
up.
Results: 56 subjects completed the study. Table 1 shows the pharmacoki-
netic parameters. Voriconazole absorption was rapid with a mean Tmax
ranging from 0.9-1.7 h across all groups. Steady-state levels were achieved
after 3-5 days of multiple dosing wirh all regimens. Voriconazole exhibited
IMoP240IQuantification of levofloxadn In bile using a HPLC
assay and a microbiological assay
S. Bottcherl , H. V. Bauml , C. Benz2, H. -G. SonntagI
1Institute ofHygiene. University ofHeidelberg; 2Dept. ofGastroentnology,
Med. Klinik C Ludwigshtifen, Germany
Objectives: This study was done to investigate the influence ofbile fluid on
two methods routinely used to determine antimicrobial agents in biological
matrices: the HPLC assay and a microbiological assay.
Methods: HPLC: A single step protein precipitation was used to isolate
Levofloxacin from the biological matrix. Levofloxacin was separated on a
C18 column and quantified by measuring the fluorescence adsorbance.
Microbiological assay: 9 mm wells were punched into IsoSensitest agar
inoculated with E. coli (ATCC 35218). Wells were filled either with sample
or calibration solution. Mter overnight culture the inhibition zones were
measured. Unknown concentrations were calculated from a calibration
curve constructed using Bennett's calculation.
Results: A good correlation between the assays was achieved [correlation
coefficient 0.959]. The slope was 0.84 ie values estimated by HLPC were
approximately 15% higher.
Using the HPLC merhod the N-oxide metabolite and the desmethyl
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metabolite of levofloxacin were detected in a concentration of 3.4% and
4.2% respectively.
Conclusion: Although a good correlation between the results of the HPLC
and the microbiological assay could be demonstrated, it seems noteworthy
that the HPLC method yielded higher Levofloxacin concentrations. One
reason for this finding might be an inhibitory effect of the bile fluid on the
microbiological assay.
IMoP241! Serum and tissue concentrations of levofloxadn in
orthopedic patients
H. V. Baum'. S. Boettcherl, R. Abel2, H. J. Gerner2• H. -G. Sonntagl
1Institute ofHygiene; 2Dept. ofOrthopedic Surgery, University ofHeidt/berg,
Germany
ObJectives: To detcrmine levofloxacin concentrations in serum and differ-
ent tissues after a single dose of 500 mg levofloxacin iv using high-liquid-
performance chromatography (HPLC)
Methods: 9 patients who underwent bone surgery and 12 patients in whom
a surgical debridement ofa decubitus ulcer was performed were included in
the study. All patients received 500 mg levoftoxacin iv as perioperative
prophylaxis. 1.5 h postdosing serum and tissue samples were obtained.
Levofloxacin concentrations were determined using a reversed phase HPLC
method after protein precipitation with acids and methanol.
Results: We obtained 83 specimens, including 21 serum samples. The mean
serum concentration was 8.70 ± 2.38 I£g/ml. Highest tissue concentrations
[mean ± SDj were reached in the skin samples (19.9 ± 9.9Ilg/rnIj. wound
tissue (17.3 ± 6.5 Ilg/mlj and granulation tissue [13.9 ± 2.59 llg/rnIj.
Concentrations in muscle [8.1 ± 1.4llg/mlj and cancellous bone [6.3 ± 3.4
Ilg/rnI) were substantially lower. Lowest concentrations were obtained in
fatty tissue [3.8 ± 1.7 Ilg/mlj and cortical bone [2.9 ± 1 Ilg/rnIj.
Conduslons: Levoftoxacin atraines peripheral target site concentrations
which exceed the MICs for most relevant pathogens after a single dose of
500 mgiv.
IMoP242I Serum and bile concentrations of Levofloxacln
after two oral doses
S. Bottcherl, H. V. Bauml,J. C. Arnold2,]. F. Riemann2• C. Benz2
t Institute ofHygiene, University ofHeidelberg; 2Department of
Gastroenterology, Med. Klinik C Ludwigshafen, Germany
Objectives: This study was designed to determine levels of Levofloxacin in
bile and serum in patients with biliary obstruction.
Methods: A total of 17 patients with nasobiliary tubes were included into
the study. Each patient received two 500 mg oral doses ofLevofloxacin (0 h;
24 h). Blood and bile samples were taken at 0; 3; 5; 24; 27 and 29 houn.
A single step protein precipitation was used to isolate Levofloxacin from
the biological matrix. Levofloxacin was separated on a C18 column and
quantified by measuring the fluorescence adsorbance at an excitation
wavelength of 295 nm and emission wavelength of 490 nm.
Results: Relevant Levotloxacin concentrations were detected in all samples
at least 3 hours postdosing. Serum and bile concentrations were at 0 h: 0 Jlg/
ml; 0 Ilg/ml; at 3 h: 5.34llg/rnI; 10.03Ilg/ml; at 5 h: 5.07 Ilg/rnI; 7.18; at 24 h:
4.23Ilg/rnI; 4.09llg/ml; at 27 h: 6.04llg/ml; 8.82llg/ml and at 29 h: 5.51 Ilg/
ml; 6.56 Ilg/ml.
A good correlation ofthe between thc mean values ofserum and the mean
values of bile was found.
The mean bile serum ratio was 1.38. Few patients yield very high levels of
Levofloxacin, which exceed the serum levels about 4 fold.
Conclusion: After oral administration of 500 mg Levofloxacin the drug
concentrations exceeded the MIC 90 values against many common biliary
pathogens in a large period of time.
IMoP243I Pharmacokinetics of the oral neuraminidase
inhibitor oseltamivir In pediatric patients
C. DOl,]. Barrett3.]. Mann3, A. Dorr2, P. Ward3
'Rache Global Development, Nurley; 2Palo Alto, United States; 3Welwyn,
United Kingdom
Badtground: Oseltamivit is a highly bioavailable prodrug ofRo 64-0802, a
potent and selective inhibitor of inftuenza A and B neuraminidases.
Objective: To evaluate pharmacokinetics ofoseltamivir in children aged 1-
12 infected with influenza virus.
Methods: Children aged 1-12 were dosed at 2 mg/kg twice daily (bid) for 5
days. Steady-state trough concentrations (Cm ;,,) from sparse sampling of 36
patients and 12-hour dense sampling of 5 patients were evaluable.
Results: Steady-state exposures ofRo 64-0802 in children aged 1-12 is half
the exposure in adolescents (13-18) and adults given comparable doses:
Ag" (yeu) 1-12 13-18* Adults* Adults*
biJdo", 2mgfkg 2mg/kg 75mg 150mg
(~1 mgfkg) (~2mgfkg)
Cmin(og/mL) 229* 234 138 288
AUC (og h/mL) 2943* 4534 2719 5466
<includes extrapolated data from previous children and .dult studies
The increase in creatinine clearance in the lower age groups could account
for the gradual decrease in systemic exposure ofRo 64-0802. Similarly. for
oseltamivir exposures in children aged 1-12, 13-18, and adults (75 and 150
mg), mean C min were 11. <5. <5. <5 ng/mL, and AUC were 162, 215,
112, 237 ng h/mL, respectively, indicating that metabolic conversion of
oseltamivit to Ro 64-0802 by esterases remains intact in young children.
Conclusion: The steady-state exposure ofa 2 mg/kg bid dose across the age
range 1- 12 years is similar to the range of exposures associated with safety
and efficacy in adults (75 mg bid).
IMoP244! nssue penetration of MK-G826, a newonce-daily
parenteral carbapenem antibiotic, In young healthy volunteers
L De Lereleirel. T. Laetheml, J. McCrea2,J. Zhang2, A. Majumdar2, D.
Musson. U. Guillaume3
IMerck & Co., Inc., Brussels, Belgium; 2Rahway, United States; 3Aster
Cephac Paris, France
Objectives: To evaluate the penetration of MK-0826 in suction-induced
skin blisten after multiple dose LV. administration.
Methods: 12 healthy subjects (mean age = 27) received 1 g LV. of MK-
0826 daily for 3 consecutive days. Twelve hours prior to the last dose, 10
uniform blisters were formed by controlled suction on the volar area of the
forearm opposite to the arm used for I.V. infusion. Following LV. admin-
istration on day 3, blister fluid (BF) and plasma (P) samples were obtained at
selected timepoints up to 24 hours postdose and analyzed for total MK-0826.
Each blister was sampled only once. Predose blister fluid and plasma samples
were also taken prior to any treatment.
Results: Mean (±SD) end ofinfusion concentration in P was 193.8 ± 30.3
Ilg/mL, Cmax in BF was 25.4 ± 4.4llg/mL at 8 hn postdose. A near-peak
level was reached in BF within 4 hrs. BF concentrations were sustained above
the provisional susceptibility breakpoint (4Ilg/mL) through 24 hn post-dose
in each subject. Mean plasma Tl/2 was 4.3 hrs. Beyond the 8 hr titnepoint.
BF concentrations were higher and declined more slowly than those in
plasma. Mean AUCO-24 was 422.1 Ilg.hr/ml in BF versus 694.4 j.lg.hr/rn1 in
P. Using the AUC ratio (BF/P), estimated penetration ofMK-0826 into BF
was 61 %. Multiple LV. doses ofMK-0826 were generally well tolerated.
Condusions: These data are supportive ofonce-daily I.V. dosing oft g MK-
0826 for the treatment of skin infections.
IMoP24S1 The pharmacokinetic rationale for the use of
meropenem in pancreatic diseases
A. F. Stupnicki1, R. Theurillar, M. W. Buchler!
tDept. of Visceral Surgery; 2Dept. ofClinica/ Pharmacology, University of
Berne, [nselspital, Switzerland
Objectives: To examine the penetration of meropenem into normal and
chronic inflamed pancreas.
Methods: 20 Patients undergoing pancreatic resection because of chronic
pancreatitis were entered in this study after given informed consent. Group
A (first 10 patients) received 500 mg ofmeropenem prior to surgery. group
B 1000 mg. Blood samples and tissue specimens (normal pancreas and
chronic inflamed pancreas) were collected from the resected pancreas speci-
men 260 (140-330) minutes after meropenem administration. The concen-
tration of meropenem in the serum and the tissue samples were determined
by High Pressure Liquid Chromatography (HPLC).
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Results: Serum concentrations at the time ofresection in group A were 2.03
mg/L, in group B 3.22 mg/L. Normal pancreatic tissue levels in group A
were between 0.35-2.53 mg/kg (mean 0.95 mg/L) and in group B 0.24-3.16
mg/kg (mean 1.59 mg/kg). In chronic inflamed pancreas tissue levels were in
group A between 0.1-1.57 mg/kg (mean 0.66 mgfkg), in group B 0.33-2.31
mgfkg (mean 1.25 mg/kg). Serum concentrations were in both groups
above the MlC 90 of the germs expected (E. Coli, Staphylococcus Aureus.
Bacteroidesfragilis) but statistically significant higher in group B. As expected,
tissue concentrations of meropenem in the normal pancreatic tissue were
higher than in fibrotic chronic inflamed pancreatic tissue and statistically
significant higher in group B.
Conclusion: Meropenem exhibits a pancreatic tissue penetration that
increases with dosage. The tissue levels achieved are comparable to other
carbapenems and usually exeeded the MIC 90. At a dosage of I g
meropenem tid it may be a valuable alternative in the trearment of severe
acute pancreatitis to delay the surgical intervention.
IMoP246IMultiple-dose pharmacokinetics of ceftazldme
during continuous venovenous hemofiltration in ICU-patients
F. Traunmiiller', P. Schenk2, H. Burgmann', I. El-Menyawi', C.
Mittermeyer2, K. Ratheiser2, F. Thalhammer'
I Dep. of Internal Medicine I; 2Dep. of Internal Medicine IV. University of
Vienna. Vienna. Austria
Objective: The aim of the study was to analyze the pharmacokinetic
parameters of ceftazidime during continuous vena-venous hemofiltration
(CVVH) with a high-flux polysulfone membrane. The optimal dosing
regimen of ceftazidime in critically ill patients with CVVH is differently
reponed.
Methods: 12 critically ill patients (5 female, 7 male) with acute renal failure
undergoing CVVH were included. All patients received 2-g ceftazidime
q8h. Ultraftltration and blood samples (from the anerial and venous line of
the extracorporal circuit) were collected immediately prior and at 45, 90,
240. 420 and 510 minutes after starting the first infusion. Additional blood
samples were collected immediately prior and 30 min after the end of
infusion of consecutive doses.
Results: The elimination half-life, hemofiltration clearance and total
removal were 4.3 ± 0.6 h, 68.0 ± 5.9 mL/min and 74.5 ± 6.5%,
respectively.
Conclusion: Ceftazidime is significantly eliminated by CVVH resulting in
dosis adjustments in patients with renal impairment. Based on the pharma-
cokinetic findings and in accordance with the pharmacodynamic properties,
it was predicted, that the ceftazidime dosage is similiar to critically ill patients
with normal renal function.
IMoP247[ Single-dose pharmacokinetics of levofloxacin
during continuous venovenous hemofiltratlon (CVVH)
F. Traunmiiller', R. Thalhammer-Scherrer2, G. Lockerl , H. Losen', R.
Schmid2, T. Staudinger', F. Thalhammerl
I Dep. of Internal Medicine I; 2Dep. ofLaboratory Medicine, University of
Vienna, Vienna, Austria
Objective: The aim of this study was to analyze the pharmacokinetics of
levofloxacin, a new and highly active f1uoroquinolone against a wide variety
of Gram-positive and Gram-negative bacteria and the optical S-(-) isomer
ofthe racemic drug substance ofloxacin, during venovenous hemoftltration.
Methods: Twelve patients received 500 mg oflevofloxacin intravenously
after staning the hemofiltration with a high-flux polyamide membrane.
Results: The mean peak levofloxacin concentration in serum were 1.9 ± 1.0
mg/l at the anerial pon, 1.5 ± 0.9 mg/l at the venous one and 1.0 ± 0.8 mgfl
in the ultraftltrate 49 min after the infusion. Mean trough levels were 0.6 ±
0.3mg/I,0.5 ± 0.2 mg/l and 0.3 ± 0.2mgjI14hourslater,respectively. The
elimination half-life, hemoftltration clearance and total removal were 8.33
± 2.61 h, 27.6 ± 8.4 ml/min and 56 ± 19%, respectively. Sieving
coefficient was 0.47 ± 0.27.
Conclusion: Levofloxacin is significantly eliminated by CVVH resulting in
dosis adjustments in patients with renal impairment. In critically ill patients
with CVVH a daily dosage of 1000 mg levofloxacin is recommended.
Funher multiple-dosis studies appear to be warranted.
IMoP248! Pharmacokinetic modelling of the bactericidal
activity of moxifloxacin against respiratory pathogens
I. Morrissey, I. Mathias, Y. Tesfaslasie, C. Dencer, M.J. Robbins, M.
Hitchens, D. Felmingham
GR Micro Ltd, London. United Kingdom
Objectives: To evaluate the bactericidal activity of moxifloxacin (MXF)
against various R Tl pathogens over 24 hours, where the concentration of
MXF simulated the pharmacokinetic (PK) elimination of a 400-mg dose
from the blood compartment.
Methods: Resistant and susceptible strains of Streptococcus pneumoniae (3),
Haemophilus in.fluenzae (3), Moraxella catarrhalis (2) and Staghylococcus aureus
(2) were investigated. Broth was inoculated to contain 10 _106 cfu/mL of
bacteria and maintained at 37°C. MXF-containing or drug-free broth was
added to the culture hourly to simulate the PK profIle ofa single 400-mg oral
dose over 24 hours. MXF concentration was confumed by bioassay and
viable count, evaluated hourly, by a spiral plating technique. The detection
limit was 1.810g10 cfu/mL (99.99% kill).
Results: The majority ofbacteria were rapidly killed within 5-6 hours. The
rate of kill was slower in one S. pneumoniae strain; the reason for this is
unclear. Both S. aureus strains showed evidence of re-growth after 12-18
hours of MXF PK simulation. This was not attributed to resistance devel-
opment. The final viable count of the ciprofloxacin-resistant S.aureus strain
after 24 hours was attributable to bacterial growth once the MXF concen-
tration reached suh-MIC levels. For the methicillin-susceptible, ciproflox-
acin-susceptible S. aureus strain, the reason for re-growth remains unclear.
This may bear little clinical significance, since the overall potency of MXF
reduced the initial viable count by 2-310g10 cfu/mL over 24 hours.
Condusions: These data confirm the excellent and rapid bactericidal activ-
ity of MXF and the reduced likelihood of resistance emergence during
therapy.
IMoP249I Telithromycin (HMR 3647), the first ketolide
antimicrobial, does not require dosage adjustment in individuals
with hepatic impairment
E. Sultan', C. Cantelloube', A. Patat2, R. Moirand3
1Aventis Pharma. Hoechsl Marion RousseljROIfUIinvilk; 2Biofrial, Remru;
JCHU Ponchaillou, Rennes, France
objectives: Telithromycin (HMR 3647), the first ketolide antimicrobial, is
being evaluated for the treatment of community-acquired respiratory tract
infections. This parallel-group study assessed the pharmacokinetics and
safety oftelithromycin in patients with hepatic impairment, in comparison
with healthy subjects.
Methods: Twelve adult patients with hepatic impairment (mean Child
Pugh score of 9.2) and 12 matching healthy subjects were enrolled. The
plasma concentrations oftelithromycin and its major metabolite, RU 76363,
and the urine concentration of telithromycin, were determined following
administration of a single oral 800 mg dose.
Results: The plasma elimination oftelithromycin was moderately modified
in patients with hepatic impairment: tl/2>'z and the mean residence time
were increased 1.4- and 1.7-fold, respectively (p < 0.001). These modifica-
tions can be accounted for by reduced metabolic clearance of telithromycin
(AUC(O-z) for RU 76363 was decreased by 40%). This was panly
compensated for by a 50% increase in the renal clearance rate (p < 0.05).
However, telithromycin Cmax tended to be 20% lower in hepatically-
impaired patients. No significant differences were noted between the two
groups in AUC(O-z) value (11.3 and 9.83 mg.h/L for patients and subjects,
respectively). No relationship was observed between the severity of the
hepatic impairment and the pharmacokinetic parameters. Treatment was
well tolerated in both groups.
Condusions: In patients with hepatic impairment, a once-daily telithromy-
cin 800 mg dose was well tolerated and produced a telithromycin exposure
comparable with healthy subjects. Thus telithromycin does not require
dosage adjustment in hepatically-impaired individuals.
IMoP250[Orlll biOllvllilllbility of the ketolide telithromycin
(HMR 3647) is similar in both elderly and young subjects
C. Perret', D. Wessels2
,Aventis Pharma. Hoechst Marion Roussel/Romainville, France; 2FARMOVS
Research Centre. Bloetllfonlaine, South Africa
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Objectives: Telithromycin (HMR 3647) is the first of a new family of
antimicrobials, the ketolides, which have been specifically developed to
provide optimal oral therapy for respiratory tract infections. In this two-way
crossover study, the oral bioavailability of telithromycin was determined in
young and elderly subjects.
Methods: Young (n = 12; 18-40 yean) and elderly (n = 12; > 65 and ~85
years) subjects were randomised to receive either a single oral dose of800 mg
(2 x 400 mg) telithromycin, or an rv infusion of400 mg (young) or 480 mg
(elderly) telithromycin over 2.5 hours, separated by a I-week washout
period. The plasma concentrations and pharmacokinetic parameters of
telithromycin and its major metabolite, RU 76363, were determined and
oral absolute bioavailability of telithromycin was calculated as follows:
AUC(O-oo) oral dose/AUC(O-oo) IV dose x Dose IVJDose oral x 100
Results: The oral absolute bioavailabillty of telithromycin was 57% in both
young and elderly subjects. The bioavailability of57% can be accounted for
primarily by first-pass hepatic loss and by a minor pre-hepatic loss. Total
clearance of telithromycin was slightly decreased in the elderly after both
oral and rv administration. All treatments were well tolerated in both
groups.
Condusions: Telithromycin has an absolute bioavailability of57% in both
young and elderly subjects and is well tolerated.
IMoP251I Telithromydn (HMR 3647) penetrates rapidly into
tonsillar tissue achieving high and prolonged tonsillar
concentrations
P. Gehannol , V. Passot2, P. Nabet2, E. Sultan2
1Hospitalier Biehat-Claude Bernard, Paris; 2Aventis Pharma; Hoeehst Marion
Roussel/Romainville, France
Objectives: Telithromycin (HMR 3647) is the first of a new family of
antimicrobials, the ketolides, which have been specifically designed for the
treatment of community-acquired respiratory tract infections, including
tonsillopharyngitis. Its potent in vitro activiry against Group A beta-
haemolytic streptococcus (GABHS), the major bacterial cause of tonsillo-
pharyngitis, extends even to macrolide-resistant strains. This open-label,
parallel-group study investigated the penetration of telithromycin into
tonsillar tissue.
Methods: Twenty adult patients (~18 years) undergoing tonsillectomy
received a once-daily oral dose of 800 mg telithromycin for 5 days.
Tonsillectomy was performed at 3 (n = 6), 12 (n = 8) or 24 (n = 6)
hours following administration of the fourth dose. Telithromycin concen-
trations in tonsils and corresponding plasma samples were determined using
a microbiological assay.
Results
kg daily doses. Blood samples were taken at 0,6, 12,24,36,48 hours after the
first LV. and from day 3 to 5 just before each 6 mg/kg daily doses. Blood
samples were also taken 15 min (peak) after each LV. doseofTeico (given in
5 min) during the first 5 days. Teico serum concentrations were assayed by a
fluorescence method (FPIA).
Results: mean serum concentration (mgfL ± SD) ofTeico (similar in the
two groups after 48 hours).
Time
(h) Group A Group B
6 12 24 36 48 6 12 24 36 48
Mean 33.3 22.1 14.2 19.9 15.2 9.7 6.4 11.7 17.1 20.9
SD 13.3 10.1 4.9 8.3 5.6 1.9 1.4 2.4 3.4 3.2
In group A, the mean serum Teico concentration remain above 14 mg/L
as soon as the first treatment day; by contrast, in group B serum concentra-
tions fall below 10 mg/L from 6 to 12 hours after the first 6 mg/kg Teica
loading dose.
Conclusion: a single loading dose of Teieo (18 mg/kg) provide adequate
serum concentrations from starting the treatment and should be choosen in
case of moderate or severe infection.
IMoP253I Cefuroxime serum concentration during
antibioprophylaxis for cardiac surgery
C. Rossi, B. Byl, F.Jacobs, M. Moerman,). M. De Smet, L. Barvais,). P.
Thys
Erasme University Hospital, Brussels, Belgium
Objectives: the optimal dosage of cefuroxime (CXM) during the first 12
hours of cardiac sugery with cardiopulmonary bypass (CBP) is Dot fully
assessed.
Methods: 17 adult patients (pts) who underwent cardiac valve replacement
or coronary artery bypass surgery were studied. The mean (±SD) age and
weight of the pts were 63.2 ± 9.6 years and 81.1 ± 7.2 kg respectively. All
pts had a normal renal function They received CXM 1500 mg intravenously
in IS minutes at induction of anaesthesia and CXM 750 mg just before
starting the CBP. The duration of surgery (mean ± SD) was 5.1 ± 0.8
hours. CBP was initiated 2.1 ± 0.3 hours after induction with a mean
duration of1.4 ± 0.3 hours. Blood was taken before and at the end (15 min)
ofthe first injection ofCXM, at the beginning (just before the first injection
of 750 mg of CXM) and at the end of CPB, 6 and 12 hours after the first
injection. CXM 3crum concentration W'ere assayed by HPLC. The lowest
limit of detection was 0.01 mg/L.
Results: mean CXM serum concentration (mg/L ± SD):
Time af,er first dose
Starting
CBP End CBP 6 h
Parameter [mean (%CV)I Hours after 4th dose
3 12 24
Concentration in tonsils (mg/kg) 3.95 (13) 0.88 (56) 0.72 (40)
Concentration in plasma (mg/L) 1.22 (24) 0.23 (139) 0.0583 (24)














Conclusions: Telithromycin rapidly penetrates into tonsillar tissue and
maintains concentrations exceeding its MIC50 (0.008-0.06 mg/L) for
GABHS (including macrolide-resistant strains) for at least 24 hours. These
results suggest that telithromycin is likely to be an effective new treatment
for GABHS tonsillopharyngitis.
IMoP252I serum concentrations of teicoplanin (Teico)
according 2 different loading dose schedules
e. Rossi, F.Jacobs, B. Byl, L. Collignon, A. Herschuelz,). P. Thys
Erasme University Hospital, Brussels, Belgium
Objective: in severe acute gram positive infections, effective and sustained
concentrations of Teico should be rapidly obtained.
Methods: 2 groups (A and B) of 8 adult patients (pts) with moderately
severe infections requiring glycopeptide treatment were studied. The mean(±SD) age and weight ofthe prs were 48.7 ± 16.3 years and 74.3 ± 13.5 kg,
respectively. All pts had a normal renal function. Group A received one
single LV. loading dose of18 mg/kg ofTeico followed 24 hours later by 6
mg/kg daily dose,. Group B received 4 LV. loading doses of6 mgflcg of
Teieo administered l2-houriy for 48 hours followed 12 hours later by 6 mg/
Condusion: the CXM serum concentration observed after CXM 1500 mg
at induction ofanaesthesia and 750 mgjust before CPB are above the MIC90
of the most of the sensitive pathogens, including methicillin-sensitive S.
aureus, particularly during the entire period of operation. Therefore, such
dosing should be suitable for cardiac surgery antibioprophylaxis.
IMoP254I Pharmacokinetics of single daily gentamidn dosing
in children with and without a hematologic malignancy
H. H. Frayha, A. Toonsi, L Mohsen, H. Baksh, M. Ashour, B. Khan
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Objectives: To evaluate the pharmacokinetics of single daily gentamicin
dosing in children with and without leukemia.
Methods: Prospective, controlled ,tudy. Children with (group 1) and
without (group 2) leukemia requiring gentamicin for suspected or docu-
mented infection were included ifthey were between the ages of1-14 years
and exhibited normal renal function. Exclusion criteria included: obesity,
hemodynamic instability, severe metabolic acidosis and liver disease, edema.
and endocarditis. All children were initially started on gentamicin 7.5 mg/
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kg/day by intravenous infusion over I hour. Serum gentamicin concentra-
tions (SGC) were measured by fluorescence polarization immunoassay at 10
minutes, 2 hours and 9 hours after completion of the first gentamicin
infusion. The IBWI, creatinine clearance (CrCI), and gentamicin elimina-
tion rate (Ke), volume of distribution (Vd), and clearance (Cl) were
determined for each subject according to standard formulas. The 2 groups
were compared for the range of Vd, Ke and Cl, and the % of children
attaining desired peak serum gentamicin levels (pGl).
Results: Thirty three children in group 1 and 26 children in group 2 were
studied. There was no difference in age, weight, height, gender, body surface
area, mw, serum creatinine, and CrCI, between the 2 groups. The
gentamicin pharmacokinetic parameters for group I were: Cl 0.12 ±
0.09 l/hr/kg; Vd0.45 ± 0.39 lfkg; and Ke 0.33 ± 0.1 hr-1. For group 2, the
parameters were as follows: CL 0.12 ± 0.06 L/hr/kg; Vd 0.45 ± 0.31 L/kg;
and Ke 0.31 ± 0.1 hr-1. These differences were not statistically significant.
The % of children attaining PGL's were 67% and 52% for groups 1 & 2
respectively.
conduslon: In this study, there was no difference in the pharmacokinetics of
gentamicin single daily dosing between children with and without leukemia.
IMoP255I The use and therapeutic drug monitoring (TOM) of
telcoplanln In the UK
E. S. R. Darley, A. P. MacGowan, 1. O. White
BCARE, Southmead Hospital, Bristol, United Kingdom
Objective: To assess current use, dosage and TOM ofteicoplanin (T) in UK.
Method: Questionnaires were sent to the 241 Microbiology laboratories
participating in UK NEQAS for antibiotic assays. Information was collected
on the choice ofglycopeptide, reasons for preference, dosing and TOM ofT,
and guidance used to achieve therapeutic dosing.
Results: 149 responses were received. 139/149 (93%) centres used T, 55
(40%) as their first choice glycopeptide. The commonest reason for this was
'no need for assays'. 79 (57%) centres used Vancomycin (V) as first choice,
the commonest reason being 'cost'. Doses recommended, frequency of use
of TDM and desired pre-dose concentrations for staphylococcal soft-tissue
infection and bacteraemia were all lower in the group which used T in
preference to V. 9/21 (43%) responses from this group stated a pre-dose
concentration should be > 20 mg/L for MRSA bacteraemia compared to
20/35 (57%) ofthose who preferred V. Of the 55 centres favouring T, 52%
rely mainly on datasheet recommendations and 11 % on assay results in
determining T doses. (n = 55). In comparison, the findings were 29% and
26% respectively from centres using V as first choice glycopeptide (n = 79).
Condusion: The majority of hospitals sampled use T. however V is the
glycopeptide of choice in 57% of these. Those preferentially using T
recommend lower doses, seek lower pre-dose concentrations and perform
less TDM when using T than those which prefer V.
P:13/2 - Pharmacodynamics and pharmacokinetics
IMoP256I Antimicrobial activity of selected non antibiotic
drugs
S. Tyski, H. Kruszewska, T. Zar~ba
Department ofAntibiotics and Microbiology, Drug Institute, Warsaw, Poland
Some drugs which do not belong to the group ofantibiotics, ego cytostatics,
anaesthetics or vasodilators may also show the antimicrobial activity. The
aim of the study was to detect and characterise the antimicrobial activity
expressed by selected non antibiotic drugs analysed during state control
performed in Drug Institute. Over 60 drugs were randomly chosen from
different groups. The surveillance study was performed on standard micro-
bial strains: S. aureus ATCC 6538 P, E. coli ATCC 8739, P. aeruginosa ATCC
15442 and C. albicans ATCC 10231. The blotting-paper discs soaked with
solutions of drugs in concentration 0.1 g or 0.1 mill ml phosphate buffer
after drying were placed onto surface of the agar medium with smeared
suitable strain. Size ofgrowth inhibition zone corresponded to antimicrobial
activity ofdrug. It was found that the following drugs inhibited growth ofat
least one ofthe examined strains: Platidiam (SO mg-amp.) Platamine (SO mg-
amp.), Sinemet (125 mg-tab!.), Sensit (50 mg-drag.), Seractil (400 mg-tab!.),
Acesan (75 mg-tabl.), Zyban (150 mg-tab!.), Sermion (4 mg-amp.), Metho-
trexat "Ebewe" (50 mg-amp.) , Naproxen (500 mg-tab!.),Benuron (500 mg-
tab!.), Tarproxen (500 mg-tab!.), Septofervex (2 mg-tab!.) and Nospa Forte
(60 mg-tab!.). It was interesting, that strong antimicrobial activity of
methotrexate was limited to Staphyloco"us aureus strain. Minimal inhibitory
concentration of methotrexate was determined by agar dilution method
with the use of 56 clinical S. aureus strains (MRSA-32. MSSA-24). For
MSSA strains, MIC50-1O J.lg/ml, MIC90-15 J.lg/m1 (range: 10-20 ",g/m1).
For MRSA strains, MICS0-20 ",g/ml, MIC90-SO ",g/ml (range: 10- > 100
J.lg/ml).
IMoP257I Comparison of ecological effects on the
oropharyngeal microflora after treatment of acute otitis media
with suspensions of cefuroxime axetil or co-amoxyclawlanate
in children
B. Lund!, C. Edlundl , B. Rynnel-Dagool , Y. Lundgren2,J. Sterner3 , C.
E. Nord l
'Huddinge University Hospital, Karolinska Institutet; 2Dalens Sjukhus; Jparsta
Medical Consulting, Stockholm, Sweden
ObjectIves: To compare the effects on the oropharyngeal microflora in
children with AOM (acute otits media) treated with either cefuroxime
axetil, administered as an inactive prodrug, or eo-amoxyclavulanate, admi-
nistered in active form, and to evaluate the efficiency ofthese two antibiotics.
Methods: In this prospective trial 19 patients, 0.5-5 years old, diagnosed
with AOM were enrolled. The children were randomised to receive either
cefuroxime axetil15 mg/kg twice daily or co-amoxyclavu1anate 13.3 mg/kg
three times daily for seven days. Nasopharygeal and saliva samples were
collected before, immediately after, and two weeks after treatment. The
saliva samples were quantitatively and qualitatively analysed with respect to
microbial content. Nasopharyngeal samples were qualitatively analysed. All
isolates were tested for /3-lactamase production.
Results: No marked difference between the groups regarding the normal
flora or colonisation of pathogens was observed. In the cefuroxime axetil-
group 85% of the subjects were infected with Streptococcus pneumoniat',
H.mophilus influenza. or Moraxella cata"halis on day 0, the corresponding
figure for day 7 and 21 was 55%. In the co-amoxyclavulanate-group the
infection rate were 85% on day 0, 40% on day 7 and 85% on day 21
respectively. The main {1-lactamase producer was M. cata"halis.
conduslons: The local high concentration of antibiotics in oropharynx
right after intake ofantibiotic suspensions seems to have little or none impact
on the microbial flora in this region, and the antibiotic conccntraion in saliva
via systemic distribution seems high enough. for both compounds, to give
rise to a disturbed oropharyngeal microbial flora. Children seems prone to
either reinfection or persistance of pathogens within two weeks after
treatment.
IMoP25SIlack of dysautonomia with use of Iinezolid and
MAO-interacting meds
c. S. Hartman, T. S. Leach, V. Le, W. M. Todd, B. Hafkin
Pharmacia and Upjohn, KalaltUJZoo, MI, United States
Objectives: Linezolid, the first oxazolidinone to complete phase III testing,
has broad activity against susceptible and resistant Gram-positive infections.
Based on preclinical and phase I data, LZD is a weak, reversible monoamine
oxidase (MAO) inhibitor. We present vital sign data on phase III patients
who had received both LZD and an MAO-interacting medication.
Methods: Vital signs from baseline (BL), day 3 (03) and end of therapy
(EOT) were compared within and between treatment groups for all
hospitalized, phase III study subjects who had received at least 24 hours of
an MAO-interacting med before the first dose ofstudy drug. P-values were
calculated within groups using a paired t-test and between groups using one-
wayANOVA.
Results: For those patients with vitals at BL, D3 and/or EOT, 226 LZD
subjects received an MAO-int. med versus 203 in the comparator arm. Use
ofinteracting meds by class were roughly proportional between groups and
included sympathomimetics, vasopressors, SSRIs and miscellaneous anti-
depressants, select analgesics, and others. Baseline temperature (Centigrade),
blood pressure (mmHg) and pulse (per minute) for the LZD and comparator
subjects were 37.5, 129/69,96, and 37.6, 127/69,95, respectively. By D3,
vitals in the LZD group were 37.0, 130/72,87 versus 37.1, 130/70,89 for
comparator (all p values> 0.21). By EOT, vitals were 36.8,129/72,89 in
lZD subjects versus 36.9, 125/71,87 for comparator (all p values> 0040).
Consistent with resolution of infection, body temperature and pulse were
significandy lower at D3 and EOT within both groups (p < 0.0002) when
compared to baseline.
